A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS)
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Myelodysplastic-stem-cell-neoantigens-targeting-autologous-T-cell-therapy (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms PACTN
- Sponsors PersImmune
- 03 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 03 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology